Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,360 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (645)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04682847 | Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers | unknown | — | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233994 | A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | unknown | N/A | 30 | Changsha Taihe HospitalOTHER_GOV |
| 1 |
| Jan 31, 2024 |
| clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05711823 | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | unknown | Phase 3 | 300 | Guangxi Medical UniversityOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05910970 | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation(PREVENT-2) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04224480 | Longitudinal Immune-phenotyping of HCC Following MK-3475 | unknown | Phase 1 | 8 | National Cancer Centre, SingaporeOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06214533 | Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery(CEBOIDS) | unknown | N/A | 60 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT05293158 | Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study(HBIG) | unknown | N/A | 5 | Medical University of GrazOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04800497 | The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC | unknown | — | 70 | University of Milano BicoccaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT06208436 | The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer | unknown | — | 250 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04883450 | PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer(PRO-TECT) | unknown | — | 126 | Kaiser PermanenteOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05962450 | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | unknown | Phase 2 | 84 | Beijing YouAn HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06205732 | A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer. | unknown | — | 100 | Qianfoshan HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06206382 | Surgical Results of Resection of Locally Advanced Pancreatic Cancer | unknown | — | 80 | Assiut UniversityOTHER | 0 | Jan 16, 2024 | clinicaltrials |
| NCT05021250 | SBRT With DIBH for HCC After TACE and Lipiodol Marking | unknown | N/A | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06194695 | DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma(CCGLC-009) | unknown | — | 100 | Ze-yang Ding, MDOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05185531 | A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma(Notable-HCC) | unknown | Phase 1 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02611453 | Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP | unknown | N/A | 40 | University of VirginiaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06178809 | Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma | unknown | — | 475 | Singlera Genomics Inc.INDUSTRY | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06144385 | A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 20 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06182865 | A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy | unknown | N/A | 10 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04422249 | A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy | unknown | N/A | 95 | Southwest Hospital, ChinaOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04324294 | Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions | unknown | Phase 1 | 200 | Cedars-Sinai Medical CenterOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05031949 | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma(CCGLC-003) | unknown | Phase 1 | 20 | Zhang Bi Xiang, MDOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05103007 | PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer(CCGLC-004) | unknown | N/A | 200 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05520801 | Primary Hepatobiliary Cancer Cohort of Central China(CCGLC-002) | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05533892 | Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC(CCGLC-007) | unknown | Phase 1 | 30 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04559607 | TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | unknown | N/A | 188 | Zhongda HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05845554 | Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma | unknown | — | 300 | Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical UniversityOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT04850430 | Gastric Venous Reconstruction After Total Pancreatectomy(GENDER) | unknown | N/A | 20 | University Hospital HeidelbergOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT03839706 | Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation(PETMRIinHCC) | unknown | N/A | 20 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04082455 | Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer | unknown | N/A | 49 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06151691 | Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach | unknown | — | 51 | Fudan UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05429190 | Validation of SMS Protocol for HCC Screening in High-risk Patients | unknown | — | 470 | Erasmus Medical CenterOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05964621 | Venous Thromboembolism in Primary Pancreatic Tumour Resection(PaTR-VTE) | unknown | — | 64 | University of ThessalyOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05600803 | Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions | unknown | — | 236 | Soonchunhyang University HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06134973 | A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. | unknown | — | 1,000 | Tianjin Third Central HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06135649 | Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy | unknown | — | 850 | Universita di VeronaOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06111326 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 83 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 31, 2024source: clinicaltrials